Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...
The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in ...
Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...
Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...
The U.S. healthcare system saw a significant 7.5% spending increase in 2023, reaching $4.9 trillion, driven largely by ...
Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...
The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...
3d
(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...
Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback